CYPHERPUNK TECHNOLOGIES INC. Variable Lease, Cost
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Variable Lease, Cost of $58.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for the quarter ending 2026-06-30 was $58.00K, a 50.43% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for the quarter ending 2026-03-31 was $58.00K, a 50.43% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for the quarter ending 2025-12-31 was $57.00K, a 14.93% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for the quarter ending 2025-09-30 was $58.00K, a 50.43% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for fiscal 2025 was $349.00K, a 24.62% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for fiscal 2024 was $463.00K, a 2.43% increase from fiscal 2023.
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for fiscal 2023 was $452.00K, a 1.57% increase from fiscal 2022.
- CYPHERPUNK TECHNOLOGIES INC. variable lease, cost for fiscal 2022 was $445.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.00K 10-Q · filed 2026-08-12 | $116.00K 10-Q · filed 2026-08-12 | $173.00K derived: sum of 3 quarters · filed 2026-08-12 | $231.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $58.00K 10-Q · filed 2026-05-14 | $115.00K derived: sum of 2 quarters · filed 2026-05-14 | $173.00K derived: sum of 3 quarters · filed 2026-05-14 | $290.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $115.00K derived: sum of 2 quarters · filed 2026-03-16 | $232.00K derived: sum of 3 quarters · filed 2026-08-12 | $349.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-12 | $175.00K derived: sum of 2 quarters · filed 2026-08-12 | $292.00K 10-Q · filed 2025-11-12 | $359.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $117.00K 10-Q · filed 2026-08-12 | $234.00K 10-Q · filed 2026-08-12 | $301.00K derived: sum of 3 quarters · filed 2026-08-12 | $418.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $117.00K 10-Q · filed 2026-05-14 | $184.00K derived: sum of 2 quarters · filed 2026-05-14 | $301.00K derived: sum of 3 quarters · filed 2026-05-14 | $416.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $184.00K derived: sum of 2 quarters · filed 2026-03-16 | $299.00K derived: sum of 3 quarters · filed 2026-03-16 | $463.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $117.00K 10-Q · filed 2025-11-12 | $232.00K derived: sum of 2 quarters · filed 2025-11-12 | $396.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $115.00K 10-Q · filed 2025-08-14 | $229.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $114.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $452.00K 10-K · filed 2025-03-26 | |||
| 2023-06-30 | $113.00K 10-Q · filed 2024-08-12 | $226.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $112.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $445.00K 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |